The study emphasized the need to treat depression and other comorbidities, including anxiety and substance use disorders.
Patients with bipolar disorder experienced significant reductions in sleep efficiency, which was not the case in patients with schizophrenia, although effect sizes for bipolar disorder were smaller overall.
Researchers examined the association between mental health conditions and the risk for chronic opioid therapy in patients with rheumatoid arthritis.
Olfactory dysfunction is a marker for a number of neuropsychiatric disorders, including Parkinson disease, Alzheimer disease, and schizophrenia.
Roughly two-thirds of patients categorized their experience with antipsychotics as more negative than positive and 34.9% endorsed an “extremely negative” experience.
Working memory is impaired in schizophrenia, and epigenetic mechanisms such as DNA methylation may contribute to illness risk.
Given the increased risk for opioid-related problems among patients with psychiatric diagnoses, the investigators advised a more cautious approach to prescribing that integrates expertise from mental health clinicians.
The results of the study point to the validity of the Research Domain Criteria initiative and suggest that neuroimaging findings may not be specific to certain psychiatric disorders.
Compared with patients without PTSD, patients with both bipolar disorder and PTSD were more likely to be women, on disability, have a lower education level, and have a lower annual household income.
Times between mood episodes longer for those in family-focused therapy versus enhanced usual care.